28 completed, 3 terminated, 3 unknown, 2 active not recruiting. 21 Phase 2, 18 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 16, Terminated 2, Unknown 2, Active not recruiting 1 |
| Phase 1 | 18 | Completed 13, Active not recruiting 2, Terminated 2, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Interleukin-12 Subunit p35: new trials by email Literature Review of Interleukin-12 Subunit p35 trials Research Report on Interleukin-12 Subunit p35
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 36 | 2018-05-30 | 2026-07-31 |
| NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy NM-IL-12 - Lymphoma, Large B-Cell, Diffuse (DLBCL) | Phase 2 | Unknown | Neumedicines Inc. | 12 | 2016-11-01 | 2016-08-03 |
| NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds NM-IL-12, Placebo - Colostomy Stoma | Phase 2 | Completed | Neumedicines Inc. | 18 | 2016-03-01 | 2018-11-16 |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) NM-IL-12 and TSEBT - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Phase 2 | Unknown | Neumedicines Inc. | 10 | 2015-12-01 | 2018-11-16 |
| Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome HemaMax, Placebo - Hematopoietic Syndrome Due to Acute Radiation Syndrome | Phase 2 | Completed | Neumedicines Inc. | 200 | 2015-01-01 | 2018-11-16 |
| Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure HemaMax, Placebo - Hematopoietic Syndrome Due to Acute Radiation Syndrome | Phase 1 | Completed | Neumedicines Inc. | 60 | 2012-08-01 | 2018-11-16 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Cetuximab, Edodekin alfa, Laboratory Biomarker Analysis - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2011-10-26 | 2026-07-29 |
| Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12 - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2011-02-01 | 2016-10-24 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma recombinant interleukin-12, aldesleukin - Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2002-12-01 | 2013-04-09 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides aldesleukin, recombinant interleukin-12, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2002-09-01 | 2013-01-16 |
| Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 60 | 2002-02-01 | 2014-05-22 |
| Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy PSA prostate cancer vaccine, recombinant interleukin-12 - Prostate Cancer | Phase 2 | Completed | University of Chicago | 13 | 2001-11-01 | 2014-03-07 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors trastuzumab, paclitaxel, recombinant interleukin-12 - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2001-11-01 | 2013-06-04 |
| Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma rituximab, recombinant interleukin-12, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 99 | 2001-10-01 | 2013-08-26 |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2001-10-01 | 2013-06-05 |
| Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer recombinant interleukin-12 - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2001-07-01 | 2013-01-23 |
| Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma recombinant interleukin-12, paclitaxel, pegylated liposomal doxorubicin hydrochloride - Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 2001-01-01 | 2013-06-19 | |
| Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer aldesleukin, recombinant interleukin-12, sargramostim - Head and Neck Cancer | Not applicable | Completed | NYU Langone Health | 2000-06-01 | 2012-11-09 | |
| Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors recombinant interleukin-12, aldesleukin, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2000-03-01 | 2013-02-01 |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma recombinant interferon alfa, recombinant interleukin-12 - Kidney Cancer, Melanoma (Skin) | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2000-03-01 | 2013-03-21 |
Showing 20 of 36. Sign in to see all of them.
Melanoma (6) · Breast Neoplasms (5) · Carcinoma, Ovarian Epithelial (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, T-Cell, Cutaneous (4) · Mycosis Fungoides (4) · Sezary Syndrome (4) · Squamous Cell Carcinoma of Head and Neck (4)
National Cancer Institute (NCI) (18) · Neumedicines Inc. (5) · Eastern Cooperative Oncology Group (2) · University of Chicago (2) · University of Southern California (2) · Alliance for Clinical Trials in Oncology (1) · Beth Israel Deaconess Medical Center (1) · Dana-Farber Cancer Institute (1) · Indiana University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NYU Langone Health (1)
United States (34)
William Carson (3) · Jeffrey S. Weber, MD, PhD (2) · Nicholas Siebers, MD (2) · Thomas F. Gajewski, MD, PhD (2) · A. Dimitrios Colevas, MD (1) · Alain Rook (1) · Anas Younes (1) · Daniel F. Hayes, MD (1) · David Avigan, MD (1) · Diwakar Davar (1) · Grant V Bochicchio, MD, MPH (GB) (1) · Jon Wigginton (1) · Lawrence D. Kaplan, MD (1) · Martha Q. Lacy, MD (1) · Michael Atkins (1)
PMID 24725395, PMID 10815886, PMID 11211153, PMID 11756154, PMID 14984966, PMID 17846226, PMID 19243818
U01CA076576 (3), N01CM17003 (2), U10CA031946 (2), N01CM00070 (1), N01CM00071 (1), P01CA081403 (1), P30CA006516 (1), P30CA014599 (1), P30CA016058 (1), P30CA016672 (1), R01CA089442 (1), R44CA192576 (1), U01CA069912 (1), U10CA025224 (1), UM1CA186690 (1)